Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Sznol on Immunotherapy in Patients With RCC

Mario Sznol, MD
Published: Saturday, Mar 19, 2016



Mario Sznol, MD, professor of Medicine, Yale Cancer Center, shares how to discuss immunotherapy as a treatment option for patients with renal cell carcinoma (RCC).

When talking to patients regarding their treatment plan, Sznol emphasizes the benefits of immunotherapy, such as durable remissions and a favorable toxicity profile.

Sznol stresses that even if patients do not respond to immunotherapy in the first-line setting, there are still other available therapies that can be used in later lines of therapy.

<<< View more from 2016 New York GU



Mario Sznol, MD, professor of Medicine, Yale Cancer Center, shares how to discuss immunotherapy as a treatment option for patients with renal cell carcinoma (RCC).

When talking to patients regarding their treatment plan, Sznol emphasizes the benefits of immunotherapy, such as durable remissions and a favorable toxicity profile.

Sznol stresses that even if patients do not respond to immunotherapy in the first-line setting, there are still other available therapies that can be used in later lines of therapy.

<<< View more from 2016 New York GU




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x